Scientific Insights Center
Explore a collection of abstracts, blogs, publications, solution demonstrations and video content. Here you can gain insights that deepen understanding and stay updated on our autoimmune and allergy technologies and solutions.
Published Scientific Communications
Machine learning classification based on a 15-autoantibody profile by a fully automated multiplexmicroarray immunoassay for autoimmune CTD diagnosis
Extended serological profiling may improve autoimmuneconnective tissue diseases (CTD) diagnosis.
Learn more
Analytical Performance of a Novel Automated Immunoassay Microarray analyzing simultaneously 5 markers associated with Celiac Disease. ACG2024.
This study assesses the analytical performance of a novel automated immunoassay microarray for autoantibodies associated with Celiac Disease. Presented at ACG 2024.
Learn more
Performance characteristics of Automated Immunoassay Microarray prototype detecting Centromere Protein B (CENP-B). AACC2023.
This study assesses the performance characteristics of a novel automated immunoassay microarray for detecting Anti-Centromere Protein B (CENP-B) antibodies. Presented at AACC 2023.
Learn more
Performance characteristics of Automated Immunoassay Microarray detecting Anti-Centromere Protein B antibodies. Immunochemistry & Immunopathology 2023.
This study assesses the performance characteristics of a novel automated immunoassay microarray for detecting Anti-Centromere Protein B (CENP-B) antibodies.
Learn more
Performance characteristics of Automated Immunoassay Microarray prototype analyzing simultaneously 11 IgG markers associated with Connective Tissue Diseases. ACR2023.
This study assesses the performance characteristics of a novel automated immunoassay microarray for detecting 11 IgG antibodies associated with Connective Tissue Diseases. Presented at ACR 2023.
Learn more
Analytical Performance of a Novel Automated Immunoassay Microarray analyzing simultaneously 15 markers associated with Connective Tissue Diseases. IFCC2024.
This study assesses the analytical performance of a novel automated immunoassay microarray for detecting 15 IgG antibodies associated with Connective Tissue Diseases. Presented at IFCC2024.
Learn more
Analytical Evaluation of Automated Immunoassay Microarray analyzing simultaneously 11 markers associated with Connective Tissue Diseases in a Spanish Reference Laboratory. ADLM2024.
This study assesses the analytical performance of a novel automated immunoassay microarray for detecting 11 antibodies associated with Connective Tissue Diseases, in a Spanish Reference Laboratory. Presented at ADLM2024.
Learn more
Automated Immunoassay Microarray for Detecting Bet v 1-Specific IgE: Performance & Findings from ECI 2024
This study assesses a fully automated immunoassay microarray for detecting Bet v 1-specific IgE, offering improved accuracy and efficiency in allergy diagnostics. Presented at ECI 2024.
Learn moreWebinars
LumiQ™ System Demonstration
Introducing LumiQ: An all-in-one Immunofluorescence (IFA) solution.
Watch now
MosaiQ® System Demonstration
Discover MosaiQ: A groundbreaking IVD solution for autoimmune diseases, allergy, and beyond.
Watch now
Advances in the Serological Evaluation of Celiac Disease
In this webinar, Celiac Disease is discussed with particular focus on advances in the diagnosis and how a multiplex approach to serological testing can support the identification of the disease.
Watch nowBlogs
Multiplexing: Streamline Autoimmune Testing with MosaiQ AiPlex® CTDplus
In the world of autoimmune diagnostics, time and accuracy are everything. Traditional serological testing often involves multiple assays, manual steps, and long turnaround times. AliveDx is changing that with the MosaiQ® AiPlex CTDplus, a fully automated multiplex microarray immunoassay designed
Learn more
How Machine Learning Is Transforming CTD Diagnosis
In-vitro diagnostics (IVD) is entering a new era, one where artificial intelligence (AI) and multiplexed immunoassays converge to deliver fast, smart and accurate results. At AliveDx, we’re proud to be at the forefront of this transformation with our MosaiQ® and
Learn more
Transforming Vasculitis Diagnostics: Multiplex Microarray Solutions for PR3, MPO & GBM Autoantibodies
In–vitro diagnostics (IVD) is undergoing a transformation, driven by automation and a syndromic approach enabled by multiplexing technologies. At AliveDx, we’re proud to lead this evolution with the MosaiQ AiPlex® VAS microarray, a fully automated multiplex immunoassay designed to detect
Learn more
Unlocking Comprehensive Insights in Autoimmune Diagnostics: The Role of Anti-DFS70 Autoantibodies
Autoimmune connective tissue diseases1 (CTD) such as lupus, Sjögren’s syndrome, and systemic sclerosis present a diagnostic challenge due to overlapping symptoms and complex antibody profiles. At AliveDx, we’re committed to the challenge of simplifying that complexity through innovative in-vitro diagnostic
Learn moreTrending Topics
Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.
-
AliveDx featured in The Guardian newspaper as one of the UK’s Best Workplaces in Biopharma
Following our recent announcement that AliveDx had been shortlisted, we’re proud to confirm that we’ve now been officially recognised as one of the UK’s Best Workplaces in Biopharma with the list now published in The Guardian. This recognition places AliveDx
-
AliveDx named one of the UK’s Best Workplaces in BioPharma™ 2025
We’re proud to announce that AliveDx has been officially recognised as one of the UK’s Best Workplaces in BioPharma™ 2025 by Great Place to Work® UK. This is a prestigious honour that places us among the top 30 biopharma companies
-
AliveDx Suisse S.A. and Transmedic sign second distribution agreement for Indonesia, Thailand, and Singapore
AliveDx Suisse S.A. (AliveDx) and Transmedic Indonesia, Thailand and Singapore have signed a second distribution agreement, enabling Transmedic to distribute the LumiQ® solution across these markets. The distribution agreement takes effect immediately. This partnership underscores AliveDx’s dedication to expanding its
-
AliveDx Suisse S.A. and Vital Care Production Distribution et Logistique SPA, sign a second distribution agreement for Algeria
AliveDx Suisse S.A. (AliveDx) and Vital Care Production Distribution et Logistique SPA (Vital Care), have signed a second distribution agreement, which will enable Vital Care to distribute the LumiQ® solution in Algeria. The distribution agreement takes effect immediately. This partnership
-
AliveDx Suisse S.A. and Medical Supplies and Services Co. Ltd. sign a Strategic Distribution Agreement in Saudi Arabia
AliveDx Suisse S.A. (AliveDx) is pleased to announce the signing of a strategic distribution agreement with Medical Supplies and Services Co. Ltd. (MediServ). This agreement enables MediServ to distribute the MosaiQ® and LumiQ® solutions across Saudi Arabia, with immediate effect.
-
AliveDx Recertified to ISO 14001 Environmental Standard
We’re proud to announce that AliveDx has achieved recertification to ISO 14001, the international standard for Environmental Management Systems (EMS). This milestone demonstrates our ongoing commitment to reducing environmental impact, improving sustainability, and maintaining operational excellence. ISO 14001 is especially
